How to take capmatinib

Capmatinib (Capmatinib) is a drug used to treat non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. Based on the presence of the mutation in the patient's tumor or plasma samples, doctors will decide whether to choose capmatinib as a treatment option. If MET exon 14 skipping mutations are not detected in the plasma sample, or if feasible, doctors may further test the tumor tissue.

The recommended dose of capmatinib is 400 mg orally twice daily. Patients can choose to take it with food or alone, depending on their individual circumstances. While taking capmatinib, patients should swallow the tablets whole and do not break, crush, or chew the tablets. If a patient misses a dose or vomits after taking a dose, it is important not to make up for the missed dose but to continue taking the next dose at the scheduled time. This ensures the stability and efficacy of the drug.

If a patient experiences adverse reactions during treatment with capmatinib, the doctor may consider adjusting the drug dose to reduce discomfort. The first dose is adjusted to 300 mg orally twice a day, and the second dose is adjusted to 200 mg orally twice a day. For patients who cannot tolerate 200 mg taken orally twice daily, their physician may recommend permanent discontinuation of capmatinib and search for other appropriate treatment options.

In short, capmatinib is a targeted treatment drug forMET exon 14 skipping mutations, and its usage and dosage should be based on the guidance of a doctor. Patients require regular follow-up and monitoring while taking capmatinib. The doctor will arrange relevant examinations, including blood tests, liver function monitoring, and heart function monitoring, to ensure the effectiveness and safety of the treatment.